Farms.com Home   Ag Industry News

FDA Explores Animal Drug Options for Screwworm Treatment

Jul 28, 2025
By Farms.com

Efforts Continue to Support Safe Treatment of NWS Cases

The U.S. Food and Drug Administration (FDA) currently has no approved animal drugs to treat or prevent New World Screwworm (NWS) in animals. However, the FDA’s Center for Veterinary Medicine (CVM) is working closely with the USDA, state partners, and international regulators to develop effective solutions.

The NWS is a serious threat to livestock, wildlife, and even pets. It requires safe and effective treatments, especially for food-producing animals. The CVM’s main role is to review data submitted by drug makers to ensure animal health and food safety.

CVM is also partnering with the Environmental Protection Agency (EPA), which regulates certain over-the-counter antiparasitic and insecticide products, to better understand available prevention tools.

Several regulatory pathways can be used to make drugs available quickly, including full FDA approval, supplemental approval, conditional approval, emergency use authorization, and extra-label use. The best option depends on factors such as the drug’s approval status and which animals it treats.

In urgent situations, emergency use or extra-label use may be the fastest way to help animals. Veterinarians are allowed to prescribe FDA-approved drugs for off-label use if they have a valid relationship with their clients and follow existing laws.

CVM is also looking at long-term safety and effectiveness, and the potential for drug resistance. The agency encourages drug companies to submit research and explore possible approval routes.


Trending Video

Season 6, Episode 10: Defining Resiliency and the Research Driving Swine Health Forward

Video: Season 6, Episode 10: Defining Resiliency and the Research Driving Swine Health Forward

Genetic research and new technologies continue to influence the future of swine health and production efficiency. In this episode, we explore how research and technology are being used to support stronger, more resilient pigs, while also improving overall production outcomes. In this episode, we are joined by Dr. Jenelle Dunkelberger, geneticist with Topigs Norsvin, to discuss both routine and emerging strategies for improving piglet, pig, and sow livability. She outlines two primary approaches to enhancing resiliency: gene editing and traditional selective breeding. Continuing the resiliency conversation, we also hear from Dr. Lucina Galina, director of technical research projects at the Pig Improvement Company. She shares insights into ongoing gene-editing work focused on PRRS, detailing the pathway to success, regulatory and practical considerations, and the questions that still remain as the technology evolves. Together, these conversations provide a closer look at how research, genetics and innovation are shaping the future of swine health and livability.